Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea.
Sojung HanDo Young KimHo Yeong LimJung Hwan YoonBaek-Yeol RyooYujeong KimKookhee KimBo Yeon KimSo Young YiDong Sook KimDo-Yeon ChoJina YuSuhyun KimJoong-Won ParkPublished in: Gut and liver (2023)
Real-life data show that the efficacy of sorafenib seems similar to that observed in clinical trials, suggesting that appropriate subsequent therapy after sorafenib might prolong patient survival.